Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.39 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.38 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.37 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.37 |
| ▸ | NQO2 | P16083 | 2/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17372585 | 0.86 | MAPT (0.56) | MAPTLMNAPOLBNQO2PDE3B | |
| SCHEMBL24659389 | 0.81 | SLC2A1 (0.50) | POLBALDH1A1NR4A2 | |
| SCHEMBL5040481 | 0.81 | ESR1 (0.40) | AMY1AAXLPOLBGRIN2DGRIN3B | |
| SCHEMBL24659325 | 0.79 | PRKDC (0.38) | MAPTAMY1AAXLGRIN2DGRIN3B | |
| SCHEMBL24659946 | 0.79 | SRC (0.40) | AMY1AAXLKDM4EPGK1GSK3B | |
| SCHEMBL28499601 | 0.79 | AXL (0.38) | MAPTHSP90AA1HSP90AB1AMY1AAXL | |
| SCHEMBL24659015 | 0.79 | MAPT (0.42) | MAPTLMNAPOLBSMN1; SMN2NR4A2 | |
| SCHEMBL24659400 | 0.78 | NTSR1 (0.39) | LMNAAMY1AAXLPDE3BPDE3A | |
| SCHEMBL5518218 | 0.77 | MAPT (0.50) | MAPTLMNAHSP90AA1HSP90AB1CRHR1 | |
| SCHEMBL19610604 | 0.77 | MAPT (0.50) | MAPTLMNAHSP90AA1HSP90AB1CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117279914-A | SOS1 inhibitor and preparation method and application thereof | 南京再明医药有限公司 | 2023-12-22 | — | — | CN | disclosed |
| WO-2022161461-A1 | SOS1 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 江苏先声药业有限公司 | 2022-08-04 | — | — | WO | disclosed |
| EP-1395564-B1 | QUINOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR | HOFFMANN LA ROCHE (CH) | 2008-02-27 | — | — | EP | disclosed |
| US-20050049413-A1 | Quinoline derivatives | MUELLER WERNER (CH) | 2005-03-03 | — | — | US | disclosed |
| US-6818767-B2 | NEUROPEPTIDE Y (NPY) ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF ARTHRITIS, CARDIOVASCULAR DISEASES, DIABETES, RENAL FAILURE, EATING DISORDERS, OR OBESITY | HOFFMANN-LA ROCHE INC. | 2004-11-16 | — | — | US | disclosed |
| US-20020198194-A1 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198194-A1 | Quinoline derivatives | NPY2R, NPY1R, NPY4R | MAPT 3753/4885LMNA 3209/4885HSP90AA1 2680/4885 |
| US-20050049413-A1 | Quinoline derivatives | NPY2R, NPY1R, NPY4R | MAPT 3753/4885LMNA 3209/4885HSP90AA1 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.